Forward P/S Multiple: Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics (VVOS) is implementing eco-friendly plastics and remote diagnostics, confirming the issuer's projected P/S ratio within the GURU.Markets chronology, where 0.20 determines the current value of the metric. Fundamentals are bolstered by high margins driven by a unique sleep apnea treatment platform, while an R&D breakthrough in non-invasive jaw correction devices promises a radical replacement for CPAP machines.
Summary analytical data breakdowns for Vivos Therapeutics (VVOS)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Vivos Therapeutics|VVOS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital vivoslife.com|VVOS - Company Aggregate Debts|Debt to Book Capitalization Ratio Vivos Therapeutics, Inc.|VVOS - Company Long-Term Debt|Company Current Liabilities Vivos Therapeutics|Quick Ratio vivoslife.com
- financial results and valuation multiples details:
VVOS - Company Net Income|Expected Profit Vivos Therapeutics|VVOS - Market Cap to Net Income Ratio|Projected Price to Earnings Vivos Therapeutics Inc|VVOS - PEG Multiple|EV/EBITDA Multiple Vivos Therapeutics, Inc|VVOS - Operating income before deduction of amortization|Earnings per share for the last twelve months Vivos Therapeutics|VVOS - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months vivoslife.com|VVOS - Net earnings per share growth this year|Earnings growth forecast for next year Vivos Therapeutics
- sales and revenue indicators:
Fundamental company analysis:VVOS (Vivos Therapeutics, Inc)
Institutional capital assesses the investment attractiveness of Vivos Therapeutics (VVOS) through the lens of the ratio between current market value and projected sales. The expected P/S metric calculates this coefficient in real-time, allowing for a comparison of the market price against the efficiency of the commercial rollout of devices under Kirk Huntsman's leadership, which confirms the asset's fundamental stability without overpaying for future growth.
Who Vivos Therapeutics competes with
Forward P/S Multiple BSX (bostonscientific.com)|EW: Market Cap to Projected Revenue|ResMed - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Corporation|ZBH: Forward P/S Multiple|COO - Market Cap to Expected Sales Ratio|ALGN (Align Corp) - Forward P/S Multiple|Globus Medical Corp (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Holdings, Inc. ATEC|Forward P/S Multiple AORT (artivion.com)|Forward P/S Multiple Enovis Corp ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|BBNX (Beta Bionics Inc) - Forward Price-to-Revenue Multiple|IRADIMED CORPORATION - Forward Price to Sales|EMBC (Embecta Health) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Tandem Diabetes Care Inc TNDM|Price-to-Projected Revenue Ratio AxoGen Inc (AXGN)|SI-BONE, Inc. (SIBN) - Projected Price to Revenue|Orthofix Corp - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio bioventus.com (BVS)|OrthoPediatrics Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Treace Medical Concepts Inc TMCI|Strata Critical Medical (SRTA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CARL (Carlsmed Medical)|Price-to-Projected Revenue Ratio rxsight.com|Forward Price-to-Revenue Multiple ClearPoint Neuro, Inc. (CLPT)|Forward P/S Multiple STXS|STIM - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Sight Sciences, Inc. SGHT|OBIO: Market Cap to Projected Revenue|ANIK: Forward Price-to-Revenue Multiple|InspireMD, Inc. - Price to Expected Revenue Ratio|zhjmedical.com (ZJYL) - Price-to-Projected Revenue Ratio|VANI (Vivani Medical Inc) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple XTNT|Market Cap to Future Revenue Ratio NeuroOne Medical Technologies NMTC|Forward P/S Multiple MODD|Forward Price-to-Revenue Multiple myomo.com MYO|Price-to-Projected Revenue Ratio Envoy Medical Inc COCH|enVVeno Medical Corp. - Price-to-Projected Revenue Ratio|SINT: Forward Price-to-Revenue Multiple|TNON (Tenon Medical, Inc.) - Market Cap to Projected Revenue|Lifeward Ltd. (LFWD) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Autonomix (AMIX)|Price-to-Projected Revenue Ratio INVO Fertility|Bone Biologics Corp. (BBLG) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple AXNX (Axonics Modulation Technologies)|BIOL (Biolase, Inc.) - Forward Price to Sales|Forward P/S Multiple DYNT (dynatronics.com)|Forward Price to Sales FNA|INVO Bioscience - Forward P/S Multiple
